- Home
- KIND vs LQDA Comparison
KIND vs LQDA Comparison
Compare KIND & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- LQDA
- Stock Information
- Founded
- KIND 2011
- LQDA 2004
- Country
- KIND United States
- LQDA United States
- Employees
- KIND N/A
- LQDA N/A
- Industry
- KIND Computer Software: Programming Data Processing
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- LQDA Health Care
- Exchange
- KIND Nasdaq
- LQDA Nasdaq
- Market Cap
- KIND 993.6M
- LQDA 929.0M
- IPO Year
- KIND N/A
- LQDA 2018
- Fundamental
- Price
- KIND $2.37
- LQDA $9.84
- Analyst Decision
- KIND Hold
- LQDA Strong Buy
- Analyst Count
- KIND 2
- LQDA 8
- Target Price
- KIND $2.75
- LQDA $27.14
- AVG Volume (30 Days)
- KIND 2.0M
- LQDA 751.9K
- Earning Date
- KIND 11-06-2024
- LQDA 11-13-2024
- Dividend Yield
- KIND N/A
- LQDA N/A
- EPS Growth
- KIND N/A
- LQDA N/A
- EPS
- KIND N/A
- LQDA N/A
- Revenue
- KIND $237,605,000.00
- LQDA $15,610,000.00
- Revenue This Year
- KIND $13.92
- LQDA N/A
- Revenue Next Year
- KIND $15.11
- LQDA $227.73
- P/E Ratio
- KIND N/A
- LQDA N/A
- Revenue Growth
- KIND 9.99
- LQDA N/A
- 52 Week Low
- KIND $1.32
- LQDA $6.19
- 52 Week High
- KIND $3.00
- LQDA $16.99
- Technical
- Relative Strength Index (RSI)
- KIND 43.49
- LQDA 33.81
- Support Level
- KIND $2.43
- LQDA $10.17
- Resistance Level
- KIND $2.56
- LQDA $10.95
- Average True Range (ATR)
- KIND 0.14
- LQDA 0.39
- MACD
- KIND -0.01
- LQDA -0.13
- Stochastic Oscillator
- KIND 3.10
- LQDA 3.79
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.